Clinical trials are research studies performed on humans to help evaluate a new medical treatment, drug, or device. However, just like a disease, there is always a possibility that each of these medical products may have different outcomes for specific groups….
Ending AIDS: World Will Fall Short of 2020 Targets
The 2020 targets set by UNAIDS to control global HIV/AIDS infection will not be met with “COVID-19 risks blowing HIV progress way off course,” officials reported. According to the 2020 Global AIDS Update, 1.7 million people worldwide were newly infected in…
Novavax Secures $1.6 Billion from U.S. Government for COVID-19 Vaccine Program
With rising numbers of COVID-19 infections and as the fight against the novel coronavirus continues, Novavax received $1.6 billion in federal funding to support the clinical development of the company’s vaccine candidate, NVX‑CoV2373. Gaithersburg, Md.-based Novavax said the funding will allow…
Want to reopen your pharma lab amid COVID-19? Consider these strategies first
COVID-19 has unleashed a logistical conundrum for pharma lab leaders: How do you keep momentum in therapeutics development, when, like all workplaces, most labs have had to either restrict use or close altogether? The answer lies, at least in part, in…
Milken Institute Teams with First Person to Explain the Race to a COVID-19 Vaccine
WASHINGTON–(BUSINESS WIRE)– The Milken Institute, the nonprofit, nonpartisan think tank, and First Person, a San Francisco design and storytelling company, together tell the urgent story of the global race for a COVID-19 vaccine in a newly released interactive experience at: https://www.covid-19vaccinetracker.org/. Developed…
2 Million COVID-19 Cases | ‘Uniquely Worse Than I Can Remember’
With the U.S. surpassing 2 million cases of COVID-19, infectious disease experts have learned a tremendous amount about SARS-CoV-2’s transmissibility, the effects of infection, and how (or how not) to treat it. David Aronoff, MD, of Vanderbilt University Medical Center in…
FDA Action Alert: Viela, Merck, Epizyme, Evoke and Regeneron
The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period. Viela Bio’s Inebilizumab for NMOSD Gaithersburg, Maryland-based Viela Bio has a target action date of June 11 for its Biologics License…
Biopharma Update on the Novel Coronavirus: June 8
FDA Actions Reissued EUAs: The FDA reissued EUAs revising which types of respirators can be decontaminated for reuse. Availability and Capability of Non-Invasive Monitoring Devices: The FDA issued new guidance that expands the availability and capability of non-invasive monitoring devices. This guidance replaces…









